The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics
The DOI matches its Crossref record; 157 of the 157 references it cites were found in a registry or an index.
Abstract
The amyloid cascade hypothesis, which posits that the deposition of the amyloid-β peptide in the brain is a central event in Alzheimer's disease pathology, has dominated research for the past twenty years. Several therapeutics that were purported to reduce amyloid-β production or aggregation have failed in Phase III clinical testing, and many others are in various stages of development. Therefore, it is timely to review the science underpinning the amyloid cascade hypothesis, consider what type of clinical trials will constitute a valid test of this hypothesis and explore whether amyloid-β-directed therapeutics will provide the medicines that are urgently needed by society for treating this devastating disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Pathogenetic studies have shown that Aβ peptide accumulation in the brain is an early and central event, 2”
From Amyloid Plaque Imaging with a Targeted MRI Contrast Agent in a Transgenic Mouse Model of Alzheimer’s Disease (2022) · cites this paper as [2]
In the citing paper
“One possible resolution is that amyloid pathology acts only as a trigger in sporadic AD (Karran et al., 2011); i.e., Aβ accumulation is necessary but insufficient to cause full-blown disease.”
From The Major Risk Factors for Alzheimer’s Disease: Age, Sex, and Genes Modulate the Microglia Response to Aβ Plaques (2019) · cites this paper as Karran et al., 2011
In the citing paper
“since it is known that the Aβ plaques act as a driver of AD pathology63 and the accumulation Aβ plaques in the brain initiates a complex multicellular neurodegenerative process.”
From Interferon signaling modulates Down syndrome-associated Alzheimer’s disease pathology in a mouse model (2025) · cites this paper as [63]
In the citing paper
“The amyloid cascade hypothesis, which dominated the field for over three decades, proposed that the abnormal accumulation of Aβ initiates a downstream cascade leading to tau hyperphosphorylation, synaptic dysfunction, and neuronal death [6, 7].”
From Toward a Unified Framework in Molecular Neurobiology of Alzheimer’s Disease: Revisiting the Pathophysiological Hypotheses (2026) · cites this paper as [7]
In the citing paper
“a possible cause of clinical failure could be the difficulty of inhibiting these proteinases without causing side effects resulting from non-targeted proteolytic inhibition on their many physiological substrates”
From Emerging Alternative Proteinases in APP Metabolism and Alzheimer’s Disease Pathogenesis: A Focus on MT1-MMP and MT5-MMP (2019) · cites this paper as Karran et al., 2011
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedMcKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429 · cited 1×
“The apolipoprotein E ( APOE ) gene represents the major genetic risk factor for A”
BackgroundAlzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268 · cited 1×
“The apolipoprotein E ( APOE ) gene represents the major genetic risk factor for A”
BackgroundA new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051 · cited 1×
“This hypothesis was further supported by the discovery that AD could also be caused by autosomal dominant mutations in presenilin 1 (PSEN1”
BackgroundVassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506 · cited 1×
“A modification of the amyloid cascade hypothesis is supported by increasing evidence from the literature that smaller, soluble oligomeric species of amyloid-β mediate either neuronal death or affect synaptic neurotransmissio”
BackgroundAssociation of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., et al. (1998) · Nature · doi:10.1038/31508 · Cited by 3,498
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
The molecular pathology of Alzheimer's disease
Selkoe, D. J. (1991) · Neuron · doi:10.1016/0896-6273(91)90052-2 · Cited by 2,708
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599
Candidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577
Amyloid deposition as the central event in the aetiology of Alzheimer’s disease
Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538
Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516
Azevedo, F. A. C., Carvalho, L. R. B., Grinberg, L. T., Farfel, J. M., Ferretti, R. E. L., Leite, R. E. P., Filho, W. J., Lent, R., & Herculano‐Houzel, S. (2009) · Journal of Comparative Neurology · doi:10.1002/cne.21974 · Cited by 2,337 · cited 1×
“and the grey matter of the cortex, which contains the majority of deposited amyloid-β, comprises 42% of the weight of the brai”
BackgroundGenome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease
the European Alzheimer's Disease Initiative Investigators, Lambert, J.-C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., Combarros, O., Zelenika, D., Bullido, M. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.439 · Cited by 2,234
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Rogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052
Jack, C. R., Albert, M. S., Knopman, D. S., McKhann, G. M., Sperling, R. A., Carrillo, M. C., Thies, B., & Phelps, C. H. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.004 · Cited by 2,042
Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012
Initiative, T. A. D. N., Hollingworth, P., CHARGE consortium, EADI1 consortium, Harold, D., Sims, R., Gerrish, A., Lambert, J.-C., Carrasquillo, M. M., Abraham, R., et al. (2011) · Nature Genetics · doi:10.1038/ng.803 · Cited by 1,997
Wolfe, M. S., Xia, W., Ostaszewski, B. L., Diehl, T. S., Kimberly, W. T., & Selkoe, D. J. (1999) · Nature · doi:10.1038/19077 · Cited by 1,916
Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model
Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G.-Q., & Mucke, L. (2007) · Science · doi:10.1126/science.1141736 · Cited by 1,892 · cited 1×
“It has also been reported, through studies in APP -transgenic mice, that a reduction in endogenous levels of tau can ameliorate some of the behavioural and other deficits that are mediated by amyloid-”
BackgroundDeficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein
De Strooper, B., Saftig, P., Craessaerts, K., Vanderstichele, H., Guhde, G., Annaert, W., Von Figura, K., & Van Leuven, F. (1998) · Nature · doi:10.1038/34910 · Cited by 1,818
Transmission and spreading of tauopathy in transgenic mouse brain
Clavaguera, F., Bolmont, T., Crowther, R. A., Abramowski, D., Frank, S., Probst, A., Fraser, G., Stalder, A. K., Beibel, M., Staufenbiel, M., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1901 · Cited by 1,803
The role of apolipoprotein E in Alzheimer's disease
Kim, J., Basak, J. M., & Holtzman, D. M. (2009) · Neuron · doi:10.1016/j.neuron.2009.06.026 · Cited by 1,661 · cited 1×
“, with APOE2, APOE3 and APOE4 being increasingly less effective at clearing amyloid-”
BackgroundPurification and cloning of amyloid precursor protein β-secretase from human brain
Sinha, S., Anderson, J. P., Barbour, R., Basi, G. S., Caccavello, R., Davis, D., Doan, M., Dovey, H. F., Frigon, N., Hong, J., et al. (1999) · Nature · doi:10.1038/990114 · Cited by 1,612
Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease
Gómez‐Isla, T., Hollister, R., West, H., Mui, S., Growdon, J. H., Petersen, R. C., Parisi, J. E., & Hyman, B. T. (1997) · Annals of Neurology · doi:10.1002/ana.410410106 · Cited by 1,489
Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity
Yan, R., Bienkowski, M. J., Shuck, M. E., Miao, H., Tory, M. C., Pauley, A. M., Brashler, J. R., Stratman, N. C., Mathews, W. R., Buhl, A. E., et al. (1999) · Nature · doi:10.1038/990107 · Cited by 1,438
Alzheimer’s Disease: The Challenge of the Second Century
Holtzman, D. M., Morris, J. C., & Goate, A. M. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002369 · Cited by 1,424
Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416 · cited 1×
“Some post-mortem studies on eight patients who were immunized with Aβ42 to produce amyloid-β-specific antibodies have also been analyse”
BackgroundShibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413 · cited 1×
“Amyloid-β is trafficked via the interstitial fluid (ISF) into the cerebrospinal fluid (CSF) via bulk flow; however, this has been shown to be a minor route for amyloid-β clearance in mice, as it only accounts for approximately 10% of amyloid-β clearanc”
BackgroundNeuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report
Nicoll, J. A. R., Wilkinson, D., Holmes, C., Steart, P., Markham, H., & Weller, R. O. (2003) · Nature Medicine · doi:10.1038/nm840 · Cited by 1,397 · cited 1×
“These data also suggest that antibodies that target amyloid plaques drive an active mechanism that removes plaques from the brai”
BackgroundArnold, S. E., Hyman, B. T., Flory, J., Damasio, A. R., & Van Hoesen, G. W. (1991) · Cerebral Cortex · doi:10.1093/cercor/1.1.103 · Cited by 1,380
DeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151261398 · Cited by 1,298 · cited 1×
“First, the 'peripheral sink' hypothesis posits that antibody capture of peripheral amyloid-β prevents the re-entry of amyloid-β from the periphery to the brain and consequently shifts the amyloid-β equilibrium in the brain so as to mediate the dissolution of deposited amyloid-”
BackgroundCorrelation Between Elevated Levels of Amyloid β-Peptide in the Brain and Cognitive Decline
Näslund, J. (2000) · JAMA · doi:10.1001/jama.283.12.1571 · Cited by 1,268 · cited 1×
“calculated that ∼10 mg of amyloid-β per brain is deposited, whereas Naslund et al”
BackgroundInverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ 42 in humans
Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S., Dence, C. S., Shah, A. R., LaRossa, G. N., Spinner, M. L., Klunk, W. E., Mathis, C. A., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20730 · Cited by 1,246
Alzheimer’s disease: Clinical trials and drug development
Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., & Kivipelto, M. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70119-8 · Cited by 1,217
An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimerʼs Disease
Galasko, D., Bennett, D., Sano, M., Ernesto, C., Thomas, R., Grundman, M., & Ferris, S. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199700112-00005 · Cited by 1,194
Identification of a Novel Aspartic Protease (Asp 2) as β-Secretase
Hussain, I., Powell, D., Howlett, D. R., Tew, D. G., Meek, T. D., Chapman, C., Gloger, I. S., Murphy, K. E., Southan, C. D., Ryan, D. M., et al. (1999) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.1999.0811 · Cited by 1,080
Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging
Rowe, C. C., Ellis, K. A., Rimajova, M., Bourgeat, P., Pike, K. E., Jones, G., Fripp, J., Tochon-Danguy, H., Morandeau, L., O'Keefe, G., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.007 · Cited by 986
Exogenous Induction of Cerebral ß-Amyloidogenesis Is Governed by Agent and Host
Meyer-Luehmann, M., Coomaraswamy, J., Bolmont, T., Kaeser, S., Schaefer, C., Kilger, E., Neuenschwander, A., Abramowski, D., Frey, P., Jaton, A. L., et al. (2006) · Science · doi:10.1126/science.1131864 · Cited by 971
Holtzman, D. M., Bales, K. R., Tenkova, T., Fagan, A. M., Parsadanian, M., Sartorius, L. J., Mackey, B., Olney, J., McKeel, D., Wozniak, D., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.050004797 · Cited by 937 · cited 1×
“How the different APOE proteins mediate their effects in AD is not definitively known, but a compelling series of experiments in PDAPP transgenic mice that harboured the human APOE genes indicate that these cognate proteins mediate the clearance of amyloid-”
BackgroundBernstein, S. L., Dupuis, N. F., Lazo, N. D., Wyttenbach, T., Condron, M. M., Bitan, G., Teplow, D. B., Shea, J.-E., Ruotolo, B. T., Robinson, C. V., et al. (2009) · Nature Chemistry · doi:10.1038/nchem.247 · Cited by 918
Age, Neuropathology, and Dementia
Savva, G. M., Wharton, S. B., Ince, P. G., Forster, G., Matthews, F. E., & Brayne, C. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0806142 · Cited by 900
Gélinas, I., Gauthier, L., McIntyre, M., & Gauthier, S. (1999) · The American Journal of Occupational Therapy · doi:10.5014/ajot.53.5.471 · Cited by 900
Iwata, N., Tsubuki, S., Takaki, Y., Watanabe, K., Sekiguchi, M., Hosoki, E., Kawashima-Morishima, M., Lee, H.-J., Hama, E., Sekine-Aizawa, Y., et al. (2000) · Nature Medicine · doi:10.1038/72237 · Cited by 867
ALZHEIMER'S DISEASE INTERNATIONAL
Graham, N., & Brodaty, H. (1997) · International Journal of Geriatric Psychiatry · doi:10.1002/(sici)1099-1166(199707)12:7<737::aid-gps625>3.0.co;2-b · Cited by 851
Staging of Alzheimer-Related Cortical Destruction
Braak, H., Braak, E., & Bohl, J. (2008) · European Neurology · doi:10.1159/000116984 · Cited by 836
APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging
Morris, J. C., Roe, C. M., Xiong, C., Fagan, A. M., Goate, A. M., Holtzman, D. M., & Mintun, M. A. (2010) · Annals of Neurology · doi:10.1002/ana.21843 · Cited by 830
Human aspartic protease memapsin 2 cleaves the β-secretase site of β-amyloid precursor protein
Lin, X., Koelsch, G., Wu, S., Downs, D., Dashti, A., & Tang, J. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.4.1456 · Cited by 776
Galasko, D. R., Bennett, D., Sano, M., Ernesto, C., Thomas, R., Grundman, M., & Ferris, S. H. (1997) · PubMed · Cited by 767
Rinne, J. O., Brooks, D. J., Rossor, M. N., Fox, N. C., Bullock, R., Klunk, W. E., Mathis, C. A., Blennow, K., Barakos, J., Okello, A. A., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70043-0 · Cited by 701
Amyloid-like Aggregates Sequester Numerous Metastable Proteins with Essential Cellular Functions
Olzscha, H., Schermann, S. M., Woerner, A. C., Pinkert, S., Hecht, M. H., Tartaglia, G. G., Vendruscolo, M., Hayer-Hartl, M., Hartl, F. U., & Vabulas, R. M. (2011) · Cell · doi:10.1016/j.cell.2010.11.050 · Cited by 692
Amyloid β Protein (Aβ) in Alzheimeri's Disease Brain
Gravina, S. A., Ho, L., Eckman, C. B., Long, K. E., Otvos, L., Younkin, L. H., Suzuki, N., & Younkin, S. G. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.13.7013 · Cited by 676
Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease
Price, J. L., McKeel, D. W., Buckles, V. D., Roe, C. M., Xiong, C., Grundman, M., Hansen, L. A., Petersen, R. C., Parisi, J. E., Dickson, D. W., et al. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.04.002 · Cited by 661
Roberson, E. D., Halabisky, B., Yoo, J. W., Yao, J., Chin, J., Yan, F., Wu, T., Hamto, P., Devidze, N., Yu, G.-Q., et al. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.4152-10.2011 · Cited by 654
Schneider, L. S., Olin, J. T., Doody, R. S., Clark, C. M., Morris, J. C., Reisberg, B., Schmitt, F. A., Grundman, M., Thomas, R. G., & Ferris, S. H. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199700112-00004 · Cited by 647
ALZHEIMER'S DISEASE INTERNATIONAL
GRAHAM, N., & BRODATY, H. (1997) · International Journal of Geriatric Psychiatry · doi:10.1002/(sici)1099-1166(199707)12:7<691::aid-gps648>3.0.co;2-f · Cited by 634
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives
Hampel, H., Frank, R., Broich, K., Teipel, S. J., Katz, R. G., Hardy, J., Herholz, K., Bokde, A. L. W., Jessen, F., Hoessler, Y. C., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3115 · Cited by 631
Jones, L., Holmans, P. A., Hamshere, M. L., Harold, D., Moskvina, V., Ivanov, D., Pocklington, A., Abraham, R., Hollingworth, P., Sims, R., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013950 · Cited by 606
Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo
Bateman, R. J., Munsell, L. Y., Morris, J. C., Swarm, R., Yarasheski, K. E., & Holtzman, D. M. (2006) · Nature Medicine · doi:10.1038/nm1438 · Cited by 599
Saido, T. C., Iwatsubo, T., Mann, D. M. A., Shimada, H., Ihara, Y., & Kawashima, S. (1995) · Neuron · doi:10.1016/0896-6273(95)90301-1 · Cited by 587 · cited 1×
“Given the avidity of amyloid-β deposition onto plaques, it is unlikely that even very substantial reductions in the levels of free amyloid-β would mediate a reduction in the formation of amyloid plaques in patients, especially as post-translational modifications of deposited amyloid-β over many years render human amyl…”
BackgroundCommon mechanisms of amyloid oligomer pathogenesis in degenerative disease
Glabe, C. G. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.04.017 · Cited by 569
DeMattos, R. B., Bales, K. R., Cummins, D. J., Paul, S. M., & Holtzman, D. M. (2002) · Science · doi:10.1126/science.1067568 · Cited by 563
World Alzheimer Report 2010: The global economic impact of dementia
Wimo, A. B., & Prince, M. J. (2010) · Cited by 559
Survival after Initial Diagnosis of Alzheimer Disease
Larson, E. B., Shadlen, M.-F., Wang, L., McCormick, W. C., Bowen, J. D., Teri, L., & Kukull, W. A. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-7-200404060-00008 · Cited by 543
Kuperstein, I., Broersen, K., Benilova, I., Rozenski, J., Jonckheere, W., Debulpaep, M., Vandersteen, A., Segers‐Nolten, I., Van Der Werf, K., Subramaniam, V., et al. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.211 · Cited by 532
Herreman, A., Hartmann, D., Annaert, W., Saftig, P., Craessaerts, K., Serneels, L., Umans, L., Schrijvers, V., Checler, F., Vanderstichele, H., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.21.11872 · Cited by 518
Self-citationTakami, M., Nagashima, Y., Sano, Y., Ishihara, S., Morishima-Kawashima, M., Funamoto, S., & Ihara, Y. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.2362-09.2009 · Cited by 498
Vekrellis, K., Ye, Z., Qiu, W. Q., Walsh, D., Hartley, D., Chesneau, V., Rosner, M. R., & Selkoe, D. J. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-05-01657.2000 · Cited by 495
Shen, J., & Kelleher, R. J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608332104 · Cited by 485 · cited 1×
“For the amyloid-β irrelevant scenario, there is a hypothesis that the FAD mutations cause a failure in PSEN function and this mediates the neuronal loss that is observed in A”
BackgroundDiagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly People
De Meyer, G. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.179 · Cited by 462 · cited 1×
“and a different diagnosis-independent analysis of the same ADNI dat”
ResultProteases and Proteolysis in Alzheimer Disease: A Multifactorial View on the Disease Process
De Strooper, B. (2010) · Physiological Reviews · doi:10.1152/physrev.00023.2009 · Cited by 455
γ-Secretase Gene Mutations in Familial Acne Inversa
Wang, B., Yang, W., Wen, W., Sun, J., Su, B., Liu, B., Ma, D., Lv, D., Wen, Y., Qu, T., et al. (2010) · Science · doi:10.1126/science.1196284 · Cited by 451
Silverberg, G. D., Mayo, M., Saul, T., Rubenstein, E., & McGuire, D. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00487-3 · Cited by 429
Aβ40 Inhibits Amyloid Deposition In Vivo
Kim, J., Onstead, L., Randle, S., Price, R., Smithson, L., Zwizinski, C., Dickson, D. W., Golde, T., & McGowan, E. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4849-06.2007 · Cited by 415
Presenilin clinical mutations can affect γ‐secretase activity by different mechanisms
Bentahir, M., Nyabi, O., Verhamme, J., Tolia, A., Horré, K., Wiltfang, J., Esselmann, H., & De Strooper, B. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03578.x · Cited by 415
Self-citationCirrito, J. R., May, P. C., O'Dell, M. A., Taylor, J. W., Parsadanian, M., Cramer, J. W., Audia, J. E., Nissen, J. S., Bales, K. R., Paul, S. M., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-26-08844.2003 · Cited by 394
Anti-Aβ Therapeutics in Alzheimer's Disease: The Need for a Paradigm Shift
Golde, T. E., Schneider, L. S., & Koo, E. H. (2011) · Neuron · doi:10.1016/j.neuron.2011.01.002 · Cited by 382
Alzheimer's Disease Amyloid Propagation by a Template-Dependent Dock-Lock Mechanism
Esler, W. P., Stimson, E. R., Jennings, J. M., Vinters, H. V., Ghilardi, J. R., Lee, J. P., Mantyh, P. W., & Maggio, J. E. (2000) · Biochemistry · doi:10.1021/bi992933h · Cited by 362
Song, W., Nadeau, P., Yuan, M., Yang, X., Shen, J., & Yankner, B. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.12.6959 · Cited by 362
Fagan, A. M., Mintun, M. A., Shah, A. R., Aldea, P., Roe, C. M., Mach, R. H., Marcus, D., Morris, J. C., & Holtzman, D. M. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900048 · Cited by 353
De Strooper, B. (2007) · EMBO reports · doi:10.1038/sj.embor.7400897 · Cited by 351
Self-citationThe Choroid Plexus‐Cerebrospinal Fluid System: From Development to Aging
Redzic, Z. B., Preston, J. E., Duncan, J. A., Chodobski, A., & Szmydynger‐Chodobska, J. (2005) · Current Topics in Developmental Biology · doi:10.1016/s0070-2153(05)71001-2 · Cited by 345
APOE genotype predicts when — not whether — one is predisposed to develop Alzheimer disease
Meyer, M. R., Tschanz, J. T., Norton, M. C., Welsh-Bohmer, K. A., Steffens, D. C., Wyse, B. W., & Breitner, J. C. S. (1998) · Nature Genetics · doi:10.1038/1206 · Cited by 334
Kumar-Singh, S., Theuns, J., Van Broeck, B., Pirici, D., Vennekens, K., Corsmit, E., Cruts, M., Dermaut, B., Wang, R., & Van Broeckhoven, C. (2006) · Human Mutation · doi:10.1002/humu.20336 · Cited by 323
A γ‐secretase inhibitor decreases amyloid‐β production in the central nervous system
Bateman, R. J., Siemers, E. R., Mawuenyega, K. G., Wen, G., Browning, K. R., Sigurdson, W. C., Yarasheski, K. E., Friedrich, S. W., DeMattos, R. B., May, P. C., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21623 · Cited by 322
Schneider, L. S., Olin, J. T., Doody, R. S., Clark, C. M., Morris, J. C., Reisberg, B., Ferris, S. H., Schmitt, F. A., Grundman, M., & Thomas, R. G. (1997) · Alzheimer Disease · doi:10.1007/978-1-4612-4116-4_64 · Cited by 303
McConlogue, L., Buttini, M., Anderson, J. P., Brigham, E. F., Chen, K. S., Freedman, S. B., Games, D., Johnson-Wood, K., Lee, M., Zeller, M., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m611687200 · Cited by 300
Alzheimer Disease and Mortality: A 15-Year Epidemiological Study
Ganguli, M., Dodge, H. H., Shen, C., Pandav, R. S., & DeKosky, S. T. (2005) · Archives of Neurology · doi:10.1001/archneur.62.5.779 · Cited by 297
Potent amyloidogenicity and pathogenicity of Aβ43
Saito, T., Suemoto, T., Brouwers, N., Sleegers, K., Funamoto, S., Mihira, N., Matsuba, Y., Yamada, K., Nilsson, P., Takano, J., et al. (2011) · Nature Neuroscience · doi:10.1038/nn.2858 · Cited by 280
Amino- and carboxyl-terminal heterogeneity of β-amyloid peptides deposited in human brain
Saido, T. C., Yamao-Harigaya, W., Iwatsubo, T., & Kawashima, S. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(96)12970-0 · Cited by 270 · cited 1×
“Given the avidity of amyloid-β deposition onto plaques, it is unlikely that even very substantial reductions in the levels of free amyloid-β would mediate a reduction in the formation of amyloid plaques in patients, especially as post-translational modifications of deposited amyloid-β over many years render human amyl…”
BackgroundCharacterizing the Appearance and Growth of Amyloid Plaques in APP/PS1 Mice
Yan, P., Bero, A. W., Cirrito, J. R., Xiao, Q., Hu, X., Wang, Y., Gonzales, E., Holtzman, D. M., & Lee, J.-M. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.2637-09.2009 · Cited by 264
Acosta-Baena, N., Sepulveda-Falla, D., Lopera-Gómez, C. M., Jaramillo-Elorza, M. C., Moreno, S., Aguirre-Acevedo, D. C., Saldarriaga, A., & Lopera, F. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70323-9 · Cited by 263
Survival in Alzheimer disease: A multiethnic, population-based study of incident cases
Helzner, E. P., Scarmeas, N., Cosentino, S., Tang, M. X., Schupf, N., & Stern, Y. (2008) · Neurology · doi:10.1212/01.wnl.0000334278.11022.42 · Cited by 245
Jankowsky, J. L., Slunt, H. H., Gonzales, V., Savonenko, A. V., Wen, J. C., Jenkins, N. A., Copeland, N. G., Younkin, L. H., Lester, H. A., Younkin, S. G., et al. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020355 · Cited by 237
Dementia: a systematic approach to identifying reversible causes.
Reisberg, . (1986) · PubMed · Cited by 217
Staging of Alzheimer-Related Cortical Destruction
Braak, H., & Braak, E. (1997) · International Psychogeriatrics · doi:10.1017/s1041610297004973 · Cited by 217
Baumeister, R., Leimer, U., Zweckbronner, I., Jakubek, C., Grünberg, J., & Haass, C. (1997) · Genes and Function · doi:10.1046/j.1365-4624.1997.00012.x · Cited by 203
Maggio, J. E., Stimson, E. R., Ghilardi, J. R., Allen, C. J., Dahl, C. E., Whitcomb, D. C., Vigna, S. R., Vinters, H. V., Labenski, M. E., & Mantyh, P. W. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.12.5462 · Cited by 196
Apolipoprotein Eε4 modifies Alzheimer's disease onset in an E280A PS1 kindred
Pastor, P., Roe, C. M., Villegas, A., Bedoya, G., Chakraverty, S., García, G., Tirado, V., Norton, J., Ríos, S., Martínez, M., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10636 · Cited by 194
The Cerebral β-Amyloid Angiopathies: Hereditary and Sporadic
Zhang-Nunes, S. X., Maat-Schieman, M. L. C., Duinen, S. G., Roos, R. A. C., Frosch, M. P., & Greenberg, S. M. (2006) · Brain Pathology · doi:10.1111/j.1750-3639.2006.tb00559.x · Cited by 193
Wolfe, M. S. (2007) · EMBO reports · doi:10.1038/sj.embor.7400896 · Cited by 192
β‐Amyloid Degradation and Alzheimer′s Disease
Wang, D.-S., Dickson, D. W., & Malter, J. S. (2006) · BioMed Research International · doi:10.1155/jbb/2006/58406 · Cited by 185
Solution State Characterization of Amyloid β-Derived Diffusible Ligands
Hepler, R. W., Grimm, K. M., Nahas, D. D., Breese, R., Dodson, E. C., Acton, P., Keller, P. M., Yeager, M., Wang, H., Shughrue, P., et al. (2006) · Biochemistry · doi:10.1021/bi061850f · Cited by 184
Sequence Diversity and Large-Scale Typing of SNPs in the Human Apolipoprotein E Gene
Nickerson, D. A., Taylor, S. L., Fullerton, S. M., Weiss, K. M., Clark, A. G., Stengård, J. H., Salomaa, V., Boerwinkle, E., & Sing, C. F. (2000) · Genome Research · doi:10.1101/gr.146900 · Cited by 184
Differential contribution of the three Aph1 genes to γ-secretase activity in vivo
Serneels, L., Dejaegere, T., Craessaerts, K., Horré, K., Jorissen, E., Tousseyn, T., Hébert, S., Coolen, M., Martens, G., Zwijsen, A., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408901102 · Cited by 179
Self-citationDementia of the Alzheimer Type
Jalbert, J. J., Daiello, L. A., & Lapane, K. L. (2008) · Epidemiologic Reviews · doi:10.1093/epirev/mxn008 · Cited by 174
Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer’s disease
Delacourte, A., Sergeant, N., Champain, D., Wattez, A., Maurage, C.-A., Lebert, F., Pasquier, F., & David, J.-P. (2002) · Neurology · doi:10.1212/wnl.59.3.398 · Cited by 168
Accelerated decline in apolipoprotein E-ϵ4 homozygotes with Alzheimer's disease
Craft, S., Teri, L., Edland, S. D., Kukull, W. A., Schellenberg, G., McCormick, W. C., Bowen, J. D., & Larson, E. B. (1998) · Neurology · doi:10.1212/wnl.51.1.149 · Cited by 152
Aβ43 is more frequent than Aβ40 in amyloid plaque cores from Alzheimer disease brains
Welander, H., Frånberg, J., Graff, C., Sundström, E., Winblad, B., & Tjernberg, L. O. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06170.x · Cited by 148
Hefendehl, J. K., Wegenast-Braun, B. M., Liebig, C., Eicke, D., Milford, D., Calhoun, M. E., Kohsaka, S., Eichner, M., & Jucker, M. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.5147-10.2011 · Cited by 138
Current Alzheimer's disease clinical trials: Methods and placebo outcomes
Schneider, L. S. S., & Sano, M. C. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.07.038 · Cited by 137
Lanz, T. A., Karmilowicz, M. J., Wood, K. M., Pozdnyakov, N., Du, P., Piotrowski, M. A., Brown, T. M., Nolan, C. E., Richter, K. E. G., Finley, J. E., et al. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.110700 · Cited by 130
Snider, B. J., Norton, J., Coats, M. A., Chakraverty, S., Hou, C. E., Jervis, R., Lendon, C. L., Goate, A. M., McKeel, D. W., & Morris, J. C. (2005) · Archives of Neurology · doi:10.1001/archneur.62.12.1821 · Cited by 129
PSENEN and NCSTN Mutations in Familial Hidradenitis Suppurativa (Acne Inversa)
Pink, A., Simpson, M. A., Brice, G. W., Smith, C. H., Desai, N., Mortimer, P. S., Barker, J. N. W. N., & Trembath, R. C. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.42 · Cited by 126
Farrer, L. A. (1997) · JAMA · doi:10.1001/jama.1997.03550160069041 · Cited by 124
Presenilins: Members of the γ-Secretase Quartets, But Part-Time Soloists Too
Wakabayashi, T., & De Strooper, B. (2008) · Physiology · doi:10.1152/physiol.00009.2008 · Cited by 123
Self-citationTseng, B. P., Esler, W. P., Clish, C. B., Stimson, E. R., Ghilardi, J. R., Vinters, H. V., Mantyh, P. W., Lee, J. P., & Maggio, J. E. (1999) · Biochemistry · doi:10.1021/bi990718v · Cited by 119
Portelius, E., Andréasson, U., Ringman, J. M., Büerger, K., Daborg, J., Buchhave, P., Hansson, O., Harmsen, A., Gustavsson, M. K., Hanse, E., et al. (2010) · Molecular Neurodegeneration · doi:10.1186/1750-1326-5-2 · Cited by 108
Hardy, J. (2005) · Biochemical Society Transactions · doi:10.1042/bst0330578 · Cited by 105
Slowing the progression of Alzheimer disease: methodologic issues.
Leber, P. D. (1997) · PubMed · Cited by 104
Genotype and phenotype in Alzheimer's disease
Holmes, C. (2002) · British Journal of Psychiatry · doi:10.1192/bjp.180.2.131 · Cited by 103
Corder, E. H., & Mellick, G. D. (2006) · BioMed Research International · doi:10.1155/jbb/2006/27601 · Cited by 103
Talking Point on the role of presenilin mutations in Alzheimer disease
Strooper, B. D. (2007) · Cited by 97
Self-citationComparison of Aβ levels in the brain of familial and sporadic Alzheimer's disease
Hellström‐Lindahl, E., Viitanen, M. H., & Marutle, A. (2009) · Neurochemistry International · doi:10.1016/j.neuint.2009.03.007 · Cited by 89
Targeting Aβ and tau in Alzheimer's disease, an early interim report
Golde, T. E., Petrucelli, L., & Lewis, J. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.07.035 · Cited by 89 · cited 1×
“The preclinical data and the clinical biomarker data for tramiprosate and tarenflurbil were not stron”
BackgroundAbramowski, D., Wiederhold, K.-H., Furrer, U., Jaton, A.-L., Neuenschwander, A., Runser, M.-J., Danner, S., Reichwald, J., Ammaturo, D., Staab, D., et al. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.140327 · Cited by 89
Stopping a thief and killer: Alzheimer's disease crisis demands greater commitment to research
Thies, W. H. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.02.002 · Cited by 81
García-Alloza, M., Subramanian, M., Thyssen, D. H., Borrelli, L. A., Fauq, A. H., Das, P., Golde, T. E., Hyman, B. T., & Bacskai, B. J. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-19 · Cited by 78
Yagishita, S., Morishima-Kawashima, M., Tanimura, Y., Ishiura, S., & Ihara, Y. (2006) · Biochemistry · doi:10.1021/bi0521846 · Cited by 71
Godbolt, A. K., Cipolotti, L., Watt, H., Fox, N. C., Janssen, J. C., & Rossor, M. N. (2004) · Archives of Neurology · doi:10.1001/archneur.61.11.1743 · Cited by 68
APOE genotype and survival in men and women with Alzheimer’s disease
Dal Forno, G., Carson, K. A., Brookmeyer, R., Troncoso, J., Kawas, C. H., & Brandt, J. (2002) · Neurology · doi:10.1212/wnl.58.7.1045 · Cited by 62
Moghekar, A., Rao, S. B., Li, M., Ruben, D. S., Mammen, A. L., Tang, X., & O’Brien, R. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.191262 · Cited by 50
Thorvaldsson, V., MacDonald, S. W. S., Fratiglioni, L., Winblad, B. G., Kivipelto, M., Laukka, E. J., Skoog, I. G., Sacuiu, S. F., Guo, X., Östling, S., et al. (2010) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617710001372 · Cited by 47
Antuono, P., Doody, R. S., Gilman, S., Huff, J., Scheltens, P., Ueda, K., & Khachaturian, Z. S. (1997) · PubMed · Cited by 43
Developing a global strategy to prevent Alzheimer's disease: Leon Thal Symposium 2010
Khachaturian, Z. S., Petersen, R. C., Snyder, P. J., Khachaturian, A. S., Aisen, P., de Leon, M., Greenberg, B. D., Kukull, W., Maruff, P., Sperling, R. A., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.02.005 · Cited by 36
Allan, C. L., & Ebmeier, K. P. (2011) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2559 · Cited by 33
NESS, D. K., Boggs, L. N., Hepburn, D. L., Gitter, B. D., Long, G. G., May, P. C., Piroozi, K. S., Schafer, K. A., & Yang, Z. (2004) · Neurobiology of Aging · doi:10.1016/s0197-4580(04)80800-5 · Cited by 33
Optimal design of clinical trials for drugs designed to slow the course of Alzheimer's disease
Mohs, R. C., Kawas, C. H., & Carrillo, M. C. (2006) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2006.04.003 · Cited by 33
The clinical syndrome of Alzheimer's disease: aspects particularly relevant to clinical trials
Mohs, R. C. (2004) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2004.00112.x · Cited by 28
Rate of Progression in Familial Alzheimer's Disease
Swearer, J. M., O’Donnell, B. F., Ingram, S. M., & Drachman, D. A. (1996) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/089198879600900104 · Cited by 27
The clinical phenotype of familial and sporadic late onset Alzheimer's disease
Holmes, C., & Lovestone, S. (2002) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.540 · Cited by 15
Blennow, K., Zetterberg, H., Wei, J., Liu, E., Black, R. S., & Grundman, M. (2010) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.05.419 · Cited by 13
Broeckhoven, C. V., & Kumar‐Singh, S. (2006) · Journal of Alzheimer s Disease · doi:10.3233/jad-2006-9s344 · Cited by 11
Research works printed but not linked: 2
- Burns, A. & Ilife, S. Dementia. BMJ 338, 405–409 (2009).
- Alzheimer, A. About a peculiar disease of the cerebral cortex. [in German] Centralblatt für Nervenheilkunde Psychiatrie 30, 177–179 (1907).
Cited by
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
“Unfortunately, many clinical trials have been inadequately designed to robustly test the amyloid hypothesis, such that negative trial results cannot be necessarily interpreted as a rejection of the amyloid hypothesis (Karran and Hardy, 2014; Karran et al., 2011).”
Scheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125
The amyloid state and its association with protein misfolding diseases.
Knowles, T. P. J., Vendruscolo, M., & Dobson, C. M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3810 · Cited by 2,382
Villemagne, V. L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K. A., Salvado, O., Szoeke, C., Macaulay, S. L., Martins, R., Maruff, P., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70044-9 · Cited by 2,279
Jansen, I. E., Savage, J. E., Watanabe, K., Bryois, J., Williams, D. M., Steinberg, S., Sealock, J., Karlsson, I. K., Hägg, S., Athanasiu, L., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0311-9 · Cited by 2,277
Metadata
- Authors
- Karran, E., Mercken, M., & Strooper, B. D.
- Affiliations
- Janssen (Belgium) (BE)
- Vlaams Instituut voor Biotechnologie (BE)
- Corresponding author
- Karran, Eric
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-08-19
- Volume
- 10
- Issue
- 9
- Pages
- 698-712
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2079749054
- Cited by
- 2,188
- References
- 157
- Citations by year
- 2026: 74 · 2025: 115 · 2024: 130 · 2023: 139 · 2022: 141 · 2021: 158 · 2020: 174 · 2019: 191 · 2018: 174 · 2017: 163 · 2016: 171 · 2015: 160 · 2014: 151 · 2013: 130 · 2012: 107
- FWCI
- 13.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- amyloid hypothesis, Alzheimer's disease, amyloid-beta, amyloid-beta aggregation, amyloid-beta production, clinical trial design, phase III trial failure, drug development
- MeSH terms
- Alzheimer Disease, Animals, Brain Chemistry, Humans, Research Design, Amyloid beta-Peptides, Treatment Failure, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Age of Onset, Disease Progression, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.